Contributions of nitrosoureas to cancer treatment.
D000477:Alkylating Agents / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents; D000971:Antineoplastic Combined Chemotherapy Protocols; D001853:Bone Marrow / Q000187:drug effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006801:Humans; D007939:Leukemia L1210 / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000628:therapy; D008223:Lymphoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D051379:Mice; D009607:Nitrosourea Compounds / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013311:Streptozocin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009607:Nitrosourea Compounds; C007028:chlorozotocin; D013311:Streptozocin